| The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. | |
| | |
MedLine Citation:
|
PMID: 17987389 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The aim of this longitudinal study was to evaluate the echocardiographic outcome of acromegalic heart disease in patients undergoing different therapeutic approaches, in order to investigate whether SSA could provide therapeutic advantages as compared with neurosurgery. In total of 36, consecutive patients undergoing SSA treatment after neurosurgery were enrolled in this study (Gr.Surg.-SSA). After 12 months of treatment, 21 patients had a controlled disease, while the remaining 15 patients displayed uncontrolled disease. Twelve acromegalic patients who did not undergo SSA treatment due to controlled disease after neurosurgery were enrolled as control group (Gr.Surg). The echocardiographic-Doppler study was performed before neurosurgery and after 12-months of follow-up. After follow-up, a significant reduction in serum GH and IGF-I values, Left Ventricular Mass index (LVMi) and LVH rate with an improvement in diastolic function was observed in both groups of patients. We found a significant reduction of LVMi either in patients with controlled disease or in those with poorly controlled disease undergoing SSA treatment. Diastolic function and of LVH percentage improved in all groups, but significantly so only in controlled patients, no significant difference in any echocardiographic parameters and in the prevalence of the LVH rate were observed between the three groups of patients at the end of follow-up. Therefore, our data appear to show that for echographic parameters medical treatment additive beneficial effects is compared to neurosurgery alone. SSA also appears to contribute to the improvement of acromegalic cardiomyopathy also in patients who did not achieve biochemical control of the disease. |
| | |
Authors:
|
Laura De Marinis; Antonio Bianchi; Gherardo Mazziotti; Marco Mettimano; Domenico Milardi; Alessandra Fusco; Vincenzo Cimino; Giulio Maira; Alfredo Pontecorvi; Andrea Giustina |
Related Documents
:
|
3180399 - Modified fontan procedure for biventricular hearts with complex forms of double-outlet ... 8773039 - Cardiovascular manifestations in aluminium phosphide poisoning with special reference t... 17575469 - Diastolic function in several stages of chronic kidney disease in patients with autosom... 3100729 - The effect of mediastinal irradiation on cardiac function of patients treated during ch... 3272219 - Exclusive double outlet right ventricle with atrioventricular concordance and pulmonary... 16999689 - Left and right ventricular function is impaired in behçet's disease. 3180399 - Modified fontan procedure for biventricular hearts with complex forms of double-outlet ... 19428269 - Cerebrospinal fluid tau as a marker of neuronal damage after epileptic seizure. 20149309 - Does acute synovitis (pseudogout) occur in patients with chronic pyrophosphate arthropa... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Pituitary Volume: 11 ISSN: 1573-7403 ISO Abbreviation: Pituitary Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-01-28 Completed Date: 2009-06-11 Revised Date: 2009-06-26 |
Medline Journal Info:
|
Nlm Unique ID: 9814578 Medline TA: Pituitary Country: United States |
Other Details:
|
Languages: eng Pagination: 13-20 Citation Subset: IM |
Affiliation:
|
Department of Endocrinology, School of Medicine, Catholic University, Via Cassia 901, Rome 00189, Italy. laurademarinis@yahoo.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acromegaly
/
blood,
complications,
therapy* Biological Markers / blood Cardiomyopathies / etiology, physiopathology, prevention & control*, ultrasonography Combined Modality Therapy Echocardiography, Doppler Female Human Growth Hormone / blood* Humans Hypertrophy, Left Ventricular / etiology, physiopathology, prevention & control*, ultrasonography Insulin-Like Growth Factor I / metabolism Longitudinal Studies Male Middle Aged Neurosurgical Procedures* Octreotide / therapeutic use* Somatostatin / analogs & derivatives, therapeutic use* Time Factors Treatment Outcome Ventricular Function, Left / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 12629-01-5/Human Growth Hormone; 51110-01-1/Somatostatin; 67763-96-6/Insulin-Like Growth Factor I; 83150-76-9/Octreotide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A randomized trial of Parents Who Care: effects on key outcomes at 24-month follow-up.
Next Document: Mate choice for genetic quality when environments vary: suggestions for empirical progress.